Subcutaneous delivery of an antibody against SARS-CoV-2 from a supramolecular hydrogel depot

Prolonged maintenance of therapeutically-relevant levels of broadly neutralizing antibodies (bnAbs) is necessary to enable passive immunization against infectious disease. Unfortunately, protection only lasts for as long as these bnAbs remain present at a sufficiently high concentration in the body....

Full description

Saved in:
Bibliographic Details
Published in:bioRxiv 2022-05
Main Authors: Kasse, Catherine M, Yu, Anthony C, Powell, Abigail E, Roth, Gillie A, Liong, Celine S, Jons, Carolyn K, Buahin, Awua, Maikawa, Caitlin L, Youssef, Sawsan, Glanville, Jacob E, Appel, Eric A
Format: Article
Language:English
Subjects:
Antibodies
Drug delivery
Hydrogels
Immunization (passive)
Infectious diseases
Nanoparticles
Pharmacokinetics
Prophylaxis
Severe acute respiratory syndrome coronavirus 2
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prolonged maintenance of therapeutically-relevant levels of broadly neutralizing antibodies (bnAbs) is necessary to enable passive immunization against infectious disease. Unfortunately, protection only lasts for as long as these bnAbs remain present at a sufficiently high concentration in the body. Poor pharmacokinetics and burdensome administration are two challenges that need to be addressed in order to make pre- and post-exposure prophylaxis with bnAbs feasible and effective. In this work, we develop a supramolecular hydrogel as an injectable, subcutaneous depot to encapsulate and deliver antibody drug cargo. This polymer-nanoparticle (PNP) hydrogel exhibits shear-thinning and self-healing properties that are required for an injectable drug delivery vehicle. In vitro drug release assays and diffusion measurements indicate that the PNP hydrogels prevent burst release and slow the release of encapsulated antibodies. Delivery of bnAbs against SARS-CoV-2 from PNP hydrogels is compared to standard routes of administration in a preclinical mouse model. We develop a multi-compartment model to understand the ability of these subcutaneous depot materials to modulate the pharmacokinetics of released antibodies; the model is extrapolated to explore the requirements needed for novel materials to successfully deliver relevant antibody therapeutics with different pharmacokinetic characteristics. Competing Interest Statement Centivax has patented Centi-C10, as it may have commercial relevance to the field of virology.
DOI:10.1101/2022.05.24.493347